Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dey has launched Zyflo CR extended-release tablets with its marketing partner, Critical Therapeutics for the prevention and treatment of asthma.
Subscribe to our email newsletter
Zyflo CR and Zyflo (zileuton tablets) are the only FDA-approved leukotriene synthesis inhibitors for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older. They are not indicated for use in the reversal of bronchospasm in acute asthma attacks, but can be continued during acute exacerbations of asthma.
The recommended dose of Zyflo CR is two 600mg extended-release tablets twice daily, within one hour after morning and evening meals, for a total daily dose of 2400mg.
Christy Taylor, executive vice president, sales, marketing and business development at Dey, said: “We are excited to partner with Critical Therapeutics to bring a twice-daily formulation of zyflo (zileuton tablets) to the many patients affected by chronic asthma. Our collaboration with Critical Therapeutics and the launch of zyflo demonstrate our commitment to developing and marketing innovative respiratory therapeutics to enhance patients’ lives.”